3Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing Twentieth informational supplement[S]. M100 S20,CLSI,2010.
4Cai JC,Zhou HW,Zhang R,et al. Emergence of Serratia marces cens,Klebsiella pneumaniae,and Escherichia coli isolates possess- ing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC2 in intensive care units of a Chinese hospital[J]. Antimicrob Agents Chemother,2008,52(6) : 2014-2018.
5Domenech Sanchez A,Pascual A,Suarez AI,et al. Activity of nine antimicrobial agents against clinical isolates of Escherich ia coli producing extended-spectrum β-lactamases and dcficicent or not in porins[J]. J Antimicrob Chemother, 2000,46 (5) : 858-859.
6Lin YC,Hsia KC,Chen YC,et al. Genetic basis of muhidrug resistance in acinetobacter clinical isolates in Taiwan[J]. Antimicrob Agents Chemother, 2010, 54(5) : 2078-2084.
1Clinical and Laboratory Standards Institute. Performance stand- ards for antimicrobial susceptibility testing, Fifteenth information- al supplement CLSI document[S]. CLSI,M100-S15. 2005.
2Clinical and Laboratory Standards Institute. Performance stand- ards for antimicrobials susceptibility testing[S]. M100-S23.
3Zarrilli R,Giannouli M,Tomasone F,et al.Carbapenem resistance in Acinetobacter baumannii:the molecular epidemic features of an emerging problem in health care facilities[J].J Infect Dev Ctries,2009,3(5):335-341.
4Zhou H,Yang Q,Yu YS,et al.Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China[J].J Clin Microbiol,2007,45(12):4054-4057.
